Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV Tat protein (Trans-Activator of Transcription) is a small, basic regulatory protein encoded by the human immunodeficiency virus type 1 (HIV-1). It is essential for efficient transcription of the integrated HIV proviral DNA, acting as a potent transactivator that dramatically increases transcription from the viral long terminal repeat (LTR) promoter. Tat binds specifically to the TAR RNA element and recruits host cellular factors, most notably P-TEFb, to stalled RNA polymerase II complexes at the LTR promoter, leading to increased production of full-length viral transcripts. Beyond its role in activating viral gene expression, Tat modulates leukocyte activation/proliferation and can be released extracellularly, contributing to immune dysfunctions and neurotoxicity associated with AIDS progression. It is considered a potential target for antiretroviral therapy development and latency-reversing agents.
Binds to TAR RNA and recruits P-TEFb to activate RNA polymerase II elongation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV Tat protein (None).